바이오인

 

 

This report represents qualitative and quantitative metrics of the next-generation sequencing (NGS) landscape and frames it into the context of various biomarker classes.

 

 

■ The NGS field is expanding and its quantitative penetrance into clinical testing is growing.

 

■ We present in this report some data illustrating the various disease classes into which NGS-based testing is penetrating-of course oncology is the leader in this space, but other disease classes are being impacted, too.

 

■ We also present here our analysis of the cancer biomarkers publications landscape, which demonstrates the patterns of penetration of specific biomarker(s) into various cancer classes-this provides the “ing material” for NGS panels that could be designed and validated on clinical samples as a means to develop NGS-based LDTs for different cancer classes.

 

■ Taken together, these results frame the market trends of NGS traversing from the research community toward clinical deployment and furthermore offer insight into how NGS-based tests may be developed in large numbers and then tested on patient populations to establish their validity and utility.

 

 

....(계속)